Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
Conclusion
Neoadjuvant TCH-P, in a nonclinical trial setting, was associated with a pCR rate of 53 % similar the reported rate in TRYPHAENA. Toxicity was manageable, with no patients experiencing symptomatic heart failure.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Clinical Trials | Docetaxel | Heart | Heart Failure | HER2 | Herceptin | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Study | Taxotere | Thrombocytopenia | Toxicology | Women